Ngā hua rapu - Keith T. Flaherty

Whakamahine hua
  1. 1
    Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

    Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma mā Keith T. Flaherty

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    MAP kinase signaling and inhibition in melanoma

    MAP kinase signaling and inhibition in melanoma mā Ryan J. Sullivan, Keith T. Flaherty

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance mā Ryan J. Sullivan, Keith T. Flaherty

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    BRAF, a target in melanoma

    BRAF, a target in melanoma mā Keith T. Flaherty, Grant A. McArthur

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Integrating BRAF/MEK inhibitors into combination therapy for melanoma

    Integrating BRAF/MEK inhibitors into combination therapy for melanoma mā Keiran S.M. Smalley, Keith T. Flaherty

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Targeting the RAS pathway in melanoma

    Targeting the RAS pathway in melanoma mā Zhenyu Ji, Keith T. Flaherty, Hensin Tsao

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

    Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways mā Xue Bai, David E. Fisher, Keith T. Flaherty

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    YAP in MAPK pathway targeted therapy resistance

    YAP in MAPK pathway targeted therapy resistance mā Keith T. Flaherty, Jennifer A. Wargo, Trever G. Bivona

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

    Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy mā Jennifer A. Lo, David E. Fisher, Keith T. Flaherty

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be

    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be mā Ryan J. Sullivan, Patricia LoRusso, Keith T. Flaherty

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Mutation-driven drug development in melanoma

    Mutation-driven drug development in melanoma mā Keith T. Flaherty, F. Stephen Hodi, Boris C. Bastian

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

    Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer mā Jennifer A. Wargo, Zachary A. Cooper, Keith T. Flaherty

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Melanoma: New Insights and New Therapies

    Melanoma: New Insights and New Therapies mā Vasiliki Nikolaou, Alexander Stratigos, Keith T. Flaherty, Hensin Tsao

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Mechanisms of resistance to immune checkpoint inhibitors

    Mechanisms of resistance to immune checkpoint inhibitors mā Russell W. Jenkins, David A. Barbie, Keith T. Flaherty

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    The Conundrum of Genetic “Drivers” in Benign Conditions

    The Conundrum of Genetic “Drivers” in Benign Conditions mā Shumei Kato, Scott M. Lippman, Keith T. Flaherty, Razelle Kurzrock

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Precision medicine for cancer with next-generation functional diagnostics

    Precision medicine for cancer with next-generation functional diagnostics mā Adam A. Friedman, Anthony Letai, David E. Fisher, Keith T. Flaherty

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

    Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma mā Neel M. Fofaria, Dennie T. Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay Srivastava

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition

    p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition mā Zhenyu Ji, Ching Ni Njauw, Michael Taylor, Victor Neel, Keith T. Flaherty, Hensin Tsao

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

    BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape mā Inna V. Fedorenko, Jennifer A. Wargo, Keith T. Flaherty, Jane L. Messina, Keiran S.M. Smalley

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    A Melanoma Molecular Disease Model

    A Melanoma Molecular Disease Model mā Smruti J. Vidwans, Keith T. Flaherty, David E. Fisher, Jay M. Tenenbaum, Michael Travers, Jeff Shrager

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: